Towards Mechanism-Based Therapies in Arrhythmogenic Cardiomyopathy

Affiliations

¹ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: jsaffitz@bidmc.harvard.edu.

Editorial

Jeffrey E Saffitz. JACC Basic Transl Sci. 2025 Aug.

. 2025 Aug;10(8):101313.

doi: 10.1016/j.jacbts.2025.05.008.

¹ Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: jsaffitz@bidmc.harvard.edu.

No abstract available

Keywords: Tideglusib; ankyrin-B; arrhythmia; arrhythmogenic cardiomyopathy; desmoglein-2.

Conflict of interest statement

Funding Support and Author Disclosure Dr Saffitz author is consultant for Implicit Bioscience and Rocket Pharmaceuticals.

1. Corrado D., Link M., Calkins H. Arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376:61–72. - PubMed
1. Malhotra N., Cavus O., Wallace M.J., et al. Evaluation of tideglusib as a disease modifying therapy in murine models of arrhythmogenic cardiomyopathy. JACC Basic Transl Sci. 2025;10(8):101281. - PubMed
1. Roberts J.D., Murphy N.P., Hamilton R.M., et al. Ankyrin-B dysfunction predisposes to arrhythmogenic cardiomyopathy and is amenable to therapy. J Clin Invest. 2019;129:3171–3184. - PMC - PubMed
1. Asimaki A., Tandri J., Huang H., et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2009;360:1075–1084. - PubMed
1. Horrigan J., Gomes T.B., Snape M., et al. A phase 2 study of AMO-02 (tideglusib) in congenital and childhood-onset myotonic dystrophy type 1 (DM1) Pediatr Neurol. 2020;112:84–93. - PubMed